Aptevo Therapeutics Valuation
| APVO Stock | USD 2.57 0.10 4.05% |
Based on Macroaxis valuation methodology, the firm appears to be overvalued. Aptevo Therapeutics shows a prevailing Real Value of $2.37 per share. The current price of the firm is $2.57. Our model approximates the value of Aptevo Therapeutics from analyzing the firm fundamentals such as Return On Equity of -2.84, shares owned by insiders of 0.01 %, and Current Valuation of (482.79 K) as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Aptevo Therapeutics' valuation include:
Price Book 0.7576 | Enterprise Value | Enterprise Value Ebitda 0.3863 | Price Sales 1.6074 | Forward PE 3.9448 |
Overvalued
Today
Please note that Aptevo Therapeutics' price fluctuation is very risky at this time. Calculation of the real value of Aptevo Therapeutics is based on 3 months time horizon. Increasing Aptevo Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Aptevo Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Aptevo Stock. However, Aptevo Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.57 | Real 2.37 | Target 21.0 | Hype 2.47 | Naive 2.58 |
The intrinsic value of Aptevo Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Aptevo Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Aptevo Therapeutics helps investors to forecast how Aptevo stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Aptevo Therapeutics more accurately as focusing exclusively on Aptevo Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Aptevo Therapeutics' intrinsic value based on its ongoing forecasts of Aptevo Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Aptevo Therapeutics' closest peers.
Aptevo Therapeutics Cash |
|
Aptevo Valuation Trend
Knowing Aptevo Therapeutics' actual value is paramount for traders when making sound investment determinations. Using both Aptevo Therapeutics' enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Aptevo Therapeutics Total Value Analysis
Aptevo Therapeutics is presently anticipated to have valuation of (482.79 K) with market capitalization of 3.6 M, debt of 4.63 M, and cash on hands of 29.43 M. The negative valuation of Aptevo Therapeutics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Aptevo Therapeutics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(482.79 K) | 3.6 M | 4.63 M | 29.43 M |
Aptevo Therapeutics Asset Utilization
One of the ways to look at asset utilization of Aptevo is to check how much profit was generated for every dollar of assets it reports. Aptevo Therapeutics shows a negative utilization of assets of -0.76 percent, losing $0.007606 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Aptevo Therapeutics shows how discouraging it operates for each dollar spent on its assets.Aptevo Therapeutics Ownership Allocation
Almost 95.15 percent of Aptevo Therapeutics outstanding shares are held by general public with 0.011 (percent) owned by insiders and only 4.84 % by other corporate entities.Aptevo Therapeutics Profitability Analysis
Net Loss for the year was (24.13 M) with loss before overhead, payroll, taxes, and interest of (302 K).About Aptevo Therapeutics Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Aptevo Therapeutics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Aptevo Therapeutics based exclusively on its fundamental and basic technical indicators. By analyzing Aptevo Therapeutics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Aptevo Therapeutics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Aptevo Therapeutics. We calculate exposure to Aptevo Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Aptevo Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -652 K | -619.4 K | |
| Pretax Profit Margin | 2.03 | 2.13 | |
| Operating Profit Margin | (8.28) | (8.69) | |
| Net Profit Margin | 12.33 | 12.95 | |
| Gross Profit Margin | 0.64 | 0.67 |
Aptevo Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 285 K | |
| Forward Price Earnings | 3.9448 |
Aptevo Therapeutics Current Valuation Indicators
Aptevo Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Aptevo Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Aptevo Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Aptevo Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Aptevo Therapeutics' worth.When determining whether Aptevo Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aptevo Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aptevo Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aptevo Therapeutics Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aptevo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Aptevo Stock, please use our How to Invest in Aptevo Therapeutics guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aptevo Therapeutics. If investors know Aptevo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aptevo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Aptevo Therapeutics is measured differently than its book value, which is the value of Aptevo that is recorded on the company's balance sheet. Investors also form their own opinion of Aptevo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aptevo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aptevo Therapeutics' market value can be influenced by many factors that don't directly affect Aptevo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aptevo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aptevo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aptevo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.